Newron Provides Update Following Type A Meeting With The FDA

Newron Pharmaceuticals SpA SIX:NWRN:

• NEWRON PROVIDES UPDATE FOLLOWING TYPE A MEETING WITH THE FDA

• NEWRON PHARMACEUTICALS SPA - FDA DISCUSSES CHANGES NEEDED TO RE-START ENIGMA-TRS 2 ENROLLMENT IN US

• NEWRON PHARMACEUTICALS SPA - TO PROPOSE CHANGES TO ADDRESS FDA CONCERNS

• NEWRON PHARMACEUTICALS SPA - ENIGMA-TRS 1 TO ENROLL AT LEAST 600 PATIENTS INTERNATIONALLY

• NEWRON PHARMACEUTICALS SPA - TO ANNOUNCE ENIGMA-TRS 1 12-WEEK RESULTS IN QIV 2026